The COVID-19 and Cancer Consortium (CCC19)

Other Efforts

While CCC19 was one of the first registry efforts focused on collecting data on patients with COVID-19 and cancer, we are not alone. On this page we have summarized the other registry efforts that we are aware of, and have provided links to their websites. We encourage reports to multiple registries although we also recognize that these reports take time and can lead to duplication of efforts.

Note: Duplicative case entry is a legitimate concern; the CCC19 registry survey instrument asks respondents to report this upon case entry. Please review this editorial in JAMA published in March 2020 regarding the concern of duplicative case entry: Editorial Concern — Possible Reporting of the Same Patients With COVID-19 in Different Reports

Cancer Specific Registries

ACS COVID-19 Registry

From ACS: "The American College of Surgeons (ACS) has developed the ACS COVID-19 Registry, which is now available to all hospitals seeking to capture meaningful data about the COVID-19 patients they treat. The overarching priority of this registry is to collect important clinical patient data for a disease about which little is known."

Inclusion: Hospitalized COVID-19 patients who did not undergo surgery as well as COVID-19 patients who did

Study Type: All hospitals can contribute. Unclear study design from website

Their project can be accessed here: ACS COVID-19 Patient Registry

ASCO Survey on COVID-19 in Oncology Registry

From ASCO: "The ASCO Registry aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry is designed to collect both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic and into 2021."

Inclusion: Patients with cancer and patients who are cancer-free receiving adjuvant cancer therapy within a year of cancer surgery, including patients receiving hormone-only adjuvant therapy and patients receiving supportive care only

Study Type: Participation required. IRB Exempt with limited patient identifying data, including home zip code, date of birth

Their project can be accessed here: ASCO COVID-19 Registry

ASH RC COVID-19 Registry for Hematologic Malignancy

From ASH: "The ASH Research Collaborative’s Data Hub launched the COVID-19 Registry and is currently capturing data on people who test positive for COVID-19 and have been or are currently being treated for hematologic malignancy. As data are received, near real-time observational data summaries will be reported for clinicians on the front line of the COVID-19 pandemic."

Inclusion: Malignant hematology patients, regardless of recovery or active treatment status

Study Type: Anybody can report a case. De-identified non-human-subjects data "will not be collected for research purposes"

Their project can be accessed here: ASH RC COVID-19 Registry

CIBMTR COVID-19 Registries

CIBMTR aims to collect detailed data regarding the diagnosis, treatment, and outcomes of COVID-19 infections in blood and bone marrow transplant recipients.

Inclusion: Any patient being reported to CIBMTR

Study Type: Mandated reporting with additional questions added to study forms

Their project can be accessed here: CIBMTR COVID-19 Registry


COVID-HEME is a peer-to-peer forum for physicians about the care of patients with hematologic malignancies during the COVID-19 pandemic. The goal of this collaborative platform is to improve and accelerate the knowledge and experience of physicians to optimize the management of patients during the pandemic.

Inclusion: N/A

Study Type: Peer-to-Peer Forum

Their project can be accessed here: COVID-HEME Forum

TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

Global lung cancer related effort being led by Drs. Leora Horn (Vanderbilt-Ingram Cancer Center) and Marina Garassino (National Cancer Institute of Milan).

Inclusion: Thoracic Cancers

Study Type: Center-based. Send an email to Jennifer Whisenant for more details on how to get involved:

UKCCMP Project

From the website: "Our objective is to identify and learn from every case of COVID-19 in cancer patients in the UK through comprehensive reporting. This disease-specific national public health response is the first phase of a broader national coronavirus disease response initiated by NHS doctors on the ground."

Inclusion: Any patient with cancer in the UK with COVID-19

Study Type: Not research and therefore does not require NHS Ethics or Research and Development Approval

Their project can be accessed here: UKCCMP Project

NCI COVID-19 in Cancer Patients Study

From the website: "The NCI COVID-19 in Cancer Patients Study, or NCCAPS, is a natural history study of COVID-19 in people with cancer. In a natural history study, researchers follow people and collect medical and other information about them over time to learn more about how a disease and its symptoms develop and change. Diagnosis and treatment of a disease are not part of natural history studies. The knowledge gained through this study will help doctors better manage treatment for people with cancer and COVID-19 in the future.
As part of the NCCAPS study, researchers will collect blood samples, medical information, and medical images from 2,000 people with cancer who also have COVID-19. Each person will be followed for up to 2 years to help doctors understand how cancer affects COVID-19 and COVID-19 affects cancer.."

Inclusion: Adults who are receiving treatment for cancer and are waiting for SARS-CoV-2 test results or who have COVID-19 now

Study Type: Not research and therefore does not require NHS Ethics or Research and Development Approval

Their project can be accessed here: NCCAP Study

ESMO-CoCARE Registry

From the website: "ESMO has launched an international collaborative project, the ESMO-CoCARE Registry, to quickly gather data and information from healthcare professionals about treatment approaches specifically focusing on the impact of SARS-CoV-2 on cancer patients who are suspected or confirmed to have the novel coronavirus disease (COVID19). Pooling real-world data will make it possible to rapidly accumulate knowledge, which will allow  to disseminate information and guidance for  patients. Ultimately the project aims to propose approaches to mitigate the risks related to COVID-19 in cancer patients. The survey is comprised of several parts, including patient demographics, COVID-19 and cancer diagnosis and treatment, and the evolution of both diseases."

Inclusion: N/A

Study Type: Registry-based. Send an email to for more details on how to get involved

Their project can be accessed here: ESMO-COCARE Registry

The Reboot: COVID-Cancer Project

Reboot Rx is an AI-powered nonprofit startup with a mission of enabling cancer patients to access new and affordable treatments faster by finding ways to repurpose already existing generic drugs for cancer care. Reboot Rx leveraged its domain expertise and AI technology to launch the Reboot: COVID-Cancer Project, a free, publicly accessible resource containing aggregated and synthesized information specifically on COVID-19 and cancer. The goal of the project is to accelerate research and inform decisions on how to best manage cancer patients who contract COVID-19.

Their project can be accessed here: Reboot RX Project

Non-Cancer Specific Registries

COVID-19 Global Rheumatology Alliance

A secure, de-identified, international case reporting registry to guide rheumatology clinicians in assessing and treating patients with rheumatologic disease and in evaluating the risk of infection in patients on immunosuppression.

Their project can be accessed here: COVID-19 Entered Registries


A registry designed to capture pediatric and adult COVID-19 cases that are occurring across the world in patients living with sickle cell disease. The goal of the registry is to report on outcomes of cases of COVID-19 in this population of patients.

Their project can be accessed here: SECURE-SCD Registry

SECURE-Cirrhosis Registry

A registry for COVID-19 in patients with chronic liver disease (with and without cirrhosis) and post-liver transplant, regardless of severity of COVID-19 (including asymptomatic patients detected through public health screening).

Their project can be accessed here: SECURE-Liver Registry


University of North Carolina (UNC) pediatric gastroenterologist Michael Kappelman, MD, MPH, GI fellow Erica Brenner, MD, and their collaborator Ryan Ungaro, MD from the Icahn School of Medicine in New York with the help from the North Carolina Translational & Clinical Sciences (NC TraCS) Institute at UNC-Chapel Hill have designed and launched an international IBD registry to capture the natural history and outcomes of children and adults with IBD in the context of COVID-19.

Using the Surveillance Epidemiology of Coronavirus Under Research Exclusion (Secure-IBD) registry, health care providers from around the globe can voluntarily report cases of IBD that also develop Coronavirus, their IBD medications, and the outcomes of Coronavirus hospitalization including recovery, hospitalization, and death.

Their project can be accessed here: SECURE-IBD Registry